Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer
Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer
Not yet recruiting · NCT07246317 · Registry updated 2025-11-28Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Not yet recruiting | Phase 2 | 2025-11-28 | NCT07246317 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Tianjin Medical University Cancer Institute and Hospital | 287 |
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Affiliated Hospital of Jiaxing University | Jiaxing | China | 2 |
| Guangdong Provincial People's Hospital | Guangzhou | China | 59 |
| Nanyang Central Hospital | Nanyang | China | 12 |
| The First Affiliated Hospital of Henan University of Science & Technology | Luoyang | China | 14 |
| The First Affiliated Hospital, Sun Yat-sen University (FAH-SYSU) | Guangzhou | China | 1 |
| The Fourth Hospital of Hebei Medical University | Shijiazhuang | China | 33 |
| The West China Second University Hospital of Sichuan University (WCSUH- SCU) | Chengdu | China | 1 |
| Tianjin Medical University Cancer Institute and Hospital | Tianjin | China | 20 |